FDA clears Verily Study Watch for additional capabilities

By Chris Newmarker | January 22, 2020

Verily’s Study Watch [Image courtesy of Verily]

Verily, Google’s life science’s sister company under Alphabet (NSDQ:GOOGL), has received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable.

Pharmaceutical industry giants including Novartis, Otsuka, Pfizer and Sanofi formed a strategic alliance with Verily last year to develop patient-centered clinical research programs using Verily’s Project Baseline evidence generation platform and tools, including the Study Watch.

Get the full story on our sister site MassDevice.